Document:

Exhibit 10.19

 

 

May 6, 2021

LifeSci Acquisition II Corp.

250 W. 55th St., #3401

New York, NY 10019

Attention: Andrew McDonald

 

Re: Support Agreement

 

Ladies and Gentlemen:

 

This letter (this “Support Agreement”)
is being delivered by each of those stockholders of Science 37, Inc., a Delaware corporation (the “Company”), whose
names appear on the signature pages of this Agreement (each, a “Stockholder” and, collectively, the “Stockholders”),
to LifeSci Acquisition II Corp., a Delaware corporation (the “Parent”), in accordance with that Merger Agreement dated
as of the date hereof, by and among the Parent, the Company and LifeSci Acquisition II Merger Sub, Inc., a Delaware corporation and wholly
owned subsidiary of the Parent (the “Merger Sub”). Capitalized terms used but not otherwise defined herein shall have
the respective meanings ascribed to such terms in the Merger Agreement. As used herein, the term “Section” shall, unless otherwise
specified, refer to the specified Section of this Support Agreement.

 

As of the date hereof, each Stockholder owns of
record the number of shares of Company Common Stock and Company Preferred Stock as set forth opposite such Stockholder’s name on
Exhibit A hereto (all such shares of Company Common Stock and Company Preferred Stock and any shares of Company Common Stock and
Company Preferred Stock of which ownership of record or the power to vote is hereafter acquired by the Stockholders prior to the termination
of this Support Agreement being referred to herein as the “Stockholder Shares”).

 

In order to induce the Parent to enter into the
Merger Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Stockholder
hereby agrees with Parent and the Company as follows:

 

1.                 
Voting Agreements. Each Stockholder, in his, her or its capacity as a stockholder of the Company, irrevocably and unconditionally
covenants and agrees that, (i) at any meeting of the Company’s stockholders related to the transactions contemplated by the Merger
Agreement or the Transaction Documents (the “Transactions”), whether annual or special and whether or not an adjourned
or postponed meeting, and however called, and (ii) in connection with any written consent of the Company’s stockholders related
to the Transactions (all such meetings or consents collectively referred to herein as the “Meeting”), such Stockholder
shall, as applicable to such Stockholder:

 

		a.	when the Meeting is held, appear at the
                                            Meeting or otherwise cause his, her or its Stockholder Shares to be counted as present thereat
                                            for the purpose of establishing a quorum;

 

    	 	1	 

     

    

 

		b.	vote (or execute and return an action by
                                            written consent), or cause to be voted at the Meeting (or validly execute and return and
                                            cause such consent to be granted with respect to), all of his, her or its Stockholder Shares
                                            in favor of each of the proposals relating to the Transactions; 

 

		c.	authorize
                                            and approve the Merger to the extent the approval of any of the Company’s stockholders
                                            is required or applicable pursuant to the Company’s Amended and Restated Certificate
                                            of Incorporation (the “Company Charter”);

 

		d.	convert each share of Company Preferred
                                            Stock into shares of Company Common Stock in accordance with the terms of the Company Charter
                                            Article IV, Section B(4)(b)(ii) and the Merger Agreement; and

 

		e.	vote (or execute and return an action by
                                            written consent), or cause to be voted at the Meeting (or validly execute and return and
                                            cause such consent to be granted with respect to), all of his, her or its Stockholder Shares
                                            against, and withhold consent with respect to, any action that would reasonably be expected
                                            to (x) impede, interfere with, delay, postpone or adversely affect the Merger or any of the
                                            Transactions (including as a result of not satisfying any of the conditions to Closing set
                                            forth in Section 8.1 or 8.2 of the Merger Agreement), (y) result in a breach of any covenant,
                                            representation or warranty or other obligation or agreement of the Company under the Merger
                                            Agreement, or (z) result in a breach of any covenant, representation or warranty or other
                                            obligation or agreement of such Stockholder contained in this Support Agreement.

 

Without limiting the
foregoing, prior to any valid termination of the Merger Agreement in accordance with 9.1, 9.2, 9.3 or 9.4 thereof, each Stockholder shall
take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary under applicable Laws to consummate
the Merger and the Transactions and on the terms and subject to the conditions set forth therein. The obligations of such Stockholder
specified in this Section 1 shall apply whether or not the Merger, any of the Transactions or any action described above is recommended
by the Company’s board of directors.

 

2.                 
Stop Transfers; Certificates. Each Stockholder agrees that except for transfers of his, her or its Stockholder Shares pursuant
to the Merger Agreement, such Stockholder shall not request that the Company register the transfer (book entry or otherwise) of any of
his, her or its Stockholder Shares if such transfer is not permitted by this Support Agreement. In furtherance of the foregoing, such
Stockholder hereby agrees to (a) place a revocable stop order on all of his, her or its Stockholder Shares subject to this Support Agreement,
and (b) notify the Company’s transfer agent (if any) in writing of such stop order and the restrictions on such Stockholder Shares
under this Section 2 and Section 4 below and direct the Company’s transfer agent (if any) not to process any attempts
by such Stockholder to Transfer any Stockholder Shares except in compliance with this Section 2 and Section 6 below.

 

    	 	2	 

     

    

 

3.                 
Termination of Company Financing Agreements. Each Stockholder, by this Agreement with respect to its Stockholder Shares,
severally and not jointly, hereby agrees to terminate, subject to the Closing and effective as of the Effective Time, (a) those certain
agreements set forth on Exhibit B attached hereto, if applicable to such Stockholder (the “Company Financing Agreements”);
(b) any management rights or side letters between the Company and such Stockholder; and (c) any rights under any letter or agreement
providing for redemption rights, put rights, purchase rights or other similar rights not generally available to stockholders of the Company
(clauses (a) through (c), collectively, the “Terminating Rights”) between such Stockholder and the Company, but excluding,
(i) for the avoidance of doubt, any rights such Stockholder may have that relate to any commercial or employment agreements or arrangements
between such Stockholder and the Company or any Subsidiary thereof, which shall survive the Closing in accordance with their respective
terms, and (ii) any indemnification, advancement of expenses and exculpation rights of any Stockholder or any of its Affiliates set forth
in the foregoing documents, which shall survive the Closing in accordance with their respective terms.

 

4.                 
Waiver. Each Stockholder hereby irrevocably and unconditionally (i) waives any rights of appraisal, dissenter’s rights
and any similar rights relating to the Merger Agreement and the consummation by the parties of the transactions contemplated thereby,
including the Merger, that such Stockholder may have under applicable law (including Section 262 of the Delaware General Corporation
Law or otherwise), (ii) consents to, on behalf of itself, the conversion of all outstanding shares of Company Preferred Stock into shares
of Company Common Stock, with such conversion to be in accordance with the terms of the Company Charter and effective as of immediately
prior to the Effective Time of the Merger, and (iii) waives, on behalf of themselves, its right to certain payments upon liquidation
of the Company pursuant to Article IV, Section 2 of the Company Charter.

 

5.                 
Damages; Remedies. Each Stockholder acknowledges and agrees that the rights of the other parties hereto to consummate the
Transactions are special, unique and of extraordinary character and that if for any reason any of the provisions of this Support Agreement
are not performed or complied with in accordance with their terms or are otherwise breached, immediate and irreparable harm or damage
would be caused for which money damages would not be an adequate remedy. Accordingly, each party hereto agrees that, in addition to any
other available remedies a party hereto may have in equity or at law, each party hereto shall be entitled to equitable remedies against
another party hereto for its breach or threatened breach of this Support Agreement, including to enforce specifically the terms and provisions
of this Support Agreement or to obtain an injunction restraining any such breach or threatened breach of the provisions of this Support
Agreement in the Chosen Courts (as defined below), in each case, (i) without necessity of posting a bond or other form of security and
(ii) without proving the inadequacy of money damages or another remedy at law. In the event that a party hereto seeks equitable remedies
in any Proceeding (including to enforce the provisions of this Support Agreement or prevent breaches or threatened breaches of this Support
Agreement), no party hereto shall raise any defense or objection, and each party hereto hereby waives any and all defenses and objections,
to such equitable remedies on grounds that (x) money damages would be adequate or there is another adequate remedy at law or (y) the
party seeking equitable remedies must either post a bond or other form of security and prove the inadequacy of money damages or another
remedy at law.

 

    	 	3	 

     

    

 

6.                 
Transfer Restrictions. Hereafter until the earlier to occur of (i) the Effective Time and (ii) such date and time as the
Merger Agreement shall be terminated in accordance with Sections 9.1, 9.2, 9.3 or 9.4 thereof, each Stockholder agrees that such Stockholder
shall not, directly or indirectly, (a) sell, assign, transfer (including by operation of Law), place a lien on, pledge, hypothecate,
grant an option to purchase, distribute, dispose of or otherwise encumber any of his, her or its Stockholder Shares except in accordance
with the Merger Agreement or otherwise enter into any contract, option or other arrangement or undertaking
to do any of the foregoing (a “Transfer”), (b) deposit any of his, her or its Stockholder Shares into a voting trust
or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect to any of his, her or its Stockholder
Shares that conflicts with any of the covenants or agreements set forth in this Support Agreement or (c) take any action that would have
the effect of preventing or materially delaying the performance of its obligations hereunder; provided, however, that nothing herein
shall prohibit a Transfer to an Affiliate of such Stockholder (a “Permitted Transfer”); provided further, that any
Permitted Transfer shall be permitted only if, as a precondition to such Transfer, the transferee also in agrees in writing, reasonably
satisfactory in form and substance to the Parent, to assume all of the obligations of such Stockholder hereunder, and be bound by the
terms of this Support Agreement. Any attempted Transfer of the Stockholder Shares, or any interest in any of the foregoing in violation
of this Section 6 shall be null and void.

 

7.                 
New Shares. During the period commencing on the date hereof and ending on the earlier to occur of (i) the Effective Time
and (ii) such date and time as the Merger Agreement shall be terminated in accordance with Sections 9.1, 9.2, 9.3 or 9.4 thereof, in
the event that, (a) any shares of Company Common Stock, Company Preferred Stock or other equity securities of Company are issued to any
Stockholder after the date of this Support Agreement pursuant to any stock dividend, stock split, recapitalization, reclassification,
combination or exchange of the Company securities owned by such Stockholder, (b) any Stockholder purchases or otherwise acquires beneficial
ownership of any shares of Company Common Stock, Company Preferred Stock or other equity securities of the Company after the date of
this Support Agreement or (c) any Stockholder acquires the right to vote or share in the voting of any Company Common Stock, Company
Preferred Stock or other equity securities of Parent after the date of this Support Agreement (such Company Common Stock, Company Preferred
Stock or other equity securities of the Company, collectively the “New Securities”), then such New Securities acquired
or purchased by such Stockholder shall be subject to the terms of this Support Agreement to the same extent as if they constituted his,
her or its Stockholder Shares as of the date hereof.

 

8.                 
Consent to Disclosure. Each Stockholder hereby consents to the publication and disclosure in the Registration Statement
(and, as and to the extent otherwise required by applicable securities Laws or the SEC or any other securities authorities, any other
documents or communications provided by the Parent or the Company to any Governmental Authority or to securityholders of the Parent)
of such Stockholder’s identity and beneficial ownership of Stockholder Shares and the nature of such Stockholder’s commitments,
arrangements and understandings under and relating to this Agreement and, if deemed appropriate by the Parent or the Company, a copy
of this Agreement, provided that any such documents shall be provided to any Stockholder being named at least one (1) business day prior
to such publishing or disclosure for review and comment by such Stockholder. Each Stockholder will promptly provide any information reasonably
requested by the Parent or the Company for any regulatory application or filing made or approval sought in connection with the Transactions
(including filings with the SEC).

 

9.                 
Entire Agreement; Amendment. This Support Agreement and the other agreements referenced herein constitute the entire agreement
and understanding of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements or
representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or
the transactions contemplated hereby. This Support Agreement may not be changed, amended, modified or waived (other than to correct a
typographical error) as to any particular provision, except by a written instrument executed by all parties hereto.

 

    	 	4	 

     

    

 

10.             
Assignment. This Support Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns. No party hereto shall be permitted to assign any of its rights or delegate any of its obligations under
this Support Agreement, in whole or in part, by operation of Law or otherwise, without the prior written consent of the other parties
hereto, and any attempted or purported assignment or delegation in violation of this Section 10 shall be null and void. Notwithstanding
anything to the contrary in this Agreement, all obligations of a party hereto are being provided on a several basis by such party and
not on a joint basis or a joint and several basis with the other parties hereto.

 

11.             
Counterparts. This Support Agreement may be executed in any number of counterparts, each such counterpart being deemed
to be an original instrument, and all such counterparts shall together constitute the same agreement. The exchange of copies of this
Support Agreement and signature pages by email in .pdf or .tif format (and including, without limitation, any electronic signature complying
with the U.S. ESIGN Act of 2000, e.g., www.docusign.com), or by any other electronic means intended to preserve the original graphic
and pictorial appearance of a document, or by combination of such means, shall constitute effective execution and delivery of this Support
Agreement as to the parties hereto and may be used in lieu of the original Support Agreement for all purposes. Such execution and delivery
shall be considered valid, binding and effective for all purposes.

 

12.             
Severability. The provisions of this Support Agreement shall be deemed severable and the illegality, invalidity or unenforceability
of any provision shall not affect the legality, validity or enforceability of the other provisions of this Support Agreement. If any
provision of this Support Agreement, or the application of such provision to any Person or any circumstance, is illegal, invalid or unenforceable,
(i) a suitable and equitable provision to be negotiated by the parties hereto, each acting reasonably and in good faith, shall be
substituted therefor in order to carry out, so far as may be legal, valid and enforceable, the intent and purpose of such legal, invalid
or unenforceable provision, and (ii) the remainder of this Support Agreement and the application of such provision to other Persons
or circumstances shall not be affected by such illegality, invalidity or unenforceability, nor shall such illegality, invalidity or unenforceability
affect the legality, validity or enforceability of such provision, or the application of such provision, in any other jurisdiction.

 

13.             
Governing Law; Jurisdiction; Jury Trial Waiver.

 

		a.	This Support Agreement, and any claims or
                                            Proceedings arising out of this Support Agreement or the subject matter hereof (whether at
                                            law or equity, in contract or in tort or otherwise), shall be governed by and construed in
                                            accordance with the laws of the State of Delaware without regard to the conflict of law principles
                                            thereof (or any other jurisdiction) to the extent that such principles would direct a matter
                                            to another jurisdiction.

 

    	 	5	 

     

    

 

		b.	Each
                                            of the parties hereto agrees that: (i) it shall bring any Proceeding in connection with,
                                            arising out of or otherwise relating to this Support Agreement, any agreement, certificate,
                                            instrument or other document delivered pursuant to this Support Agreement or the Transactions
                                            exclusively in the Court of Chancery of the State of Delaware, or (and only if) such court
                                            finds it lacks subject matter jurisdiction, the Superior Court of the State of Delaware (Complex
                                            Commercial Division); provided that if subject matter jurisdiction over the Proceeding
                                            is vested exclusively in the United States federal courts, then such Proceeding shall be
                                            heard in the United States District Court for the District of Delaware (the “Chosen
                                            Courts”); and (ii) solely in connection with such Proceedings, (1) it irrevocably
                                            and unconditionally submits to the exclusive jurisdiction of the Chosen Courts, (2) it waives
                                            any objection to the laying of venue in any Proceeding in the Chosen Courts, (3) it waives
                                            any objection that the Chosen Courts are an inconvenient forum or do not have jurisdiction
                                            over any party, (4) mailing of process or other papers in connection with any such Proceeding
                                            in the manner provided in Section 11.6 of the Merger Agreement or in such other manner
                                            as may be permitted by applicable Law shall be valid and sufficient service thereof and (5) it
                                            shall not assert as a defense, any matter or claim waived by the foregoing clauses (1) through
                                            (4) of this Section 13 or that any Governmental Order issued by the Chosen Courts
                                            may not be enforced in or by the Chosen Courts.

 

		c.	EACH
                                            OF THE PARTIES HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY BE IN CONNECTION
                                            WITH, ARISE OUT OF OR OTHERWISE RELATE TO THIS SUPPORT AGREEMENT, ANY INSTRUMENT OR OTHER
                                            DOCUMENT DELIVERED PURSUANT TO THIS SUPPORT AGREEMENT OR THE TRANSACTIONS IS LIKELY TO INVOLVE
                                            COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH OF THE PARTIES HERETO IRREVOCABLY AND
                                            UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY
                                            HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY PROCEEDING DIRECTLY OR INDIRECTLY, IN CONNECTION
                                            WITH, ARISING OUT OF OR OTHERWISE RELATING TO THIS SUPPORT AGREEMENT, ANY INSTRUMENT OR OTHER
                                            DOCUMENT DELIVERED PURSUANT TO THIS SUPPORT AGREEMENT OR THE TRANSACTIONS. EACH OF THE PARTIES
                                            HERETO HEREBY ACKNOWLEDGES AND CERTIFIES (A) THAT NO REPRESENTATIVE OF THE OTHER PARTIES
                                            HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTIES WOULD NOT, IN THE
                                            EVENT OF ANY ACTION OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) IT UNDERSTANDS
                                            AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) IT MAKES THIS WAIVER VOLUNTARILY
                                            AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS SUPPORT AGREEMENT AND THE TRANSACTIONS, BY,
                                            AMONG OTHER THINGS, THE MUTUAL WAIVERS, ACKNOWLEDGMENTS AND CERTIFICATIONS CONTAINED IN THIS
                                            SECTION 13.

 

14.             
Notice. Any notice, consent or request to be given in connection with any of the terms or provisions of this Support Agreement
shall be in writing and shall be sent or given in accordance with the terms of Section 11.6 of the Merger Agreement to the applicable
party, with respect to the Company, at the address set forth in Section 11.6 of the Merger Agreement, and, with respect to the Stockholders,
at the address set forth on each Stockholder’s signature page.

 

    	 	6	 

     

    

 

15.             
Termination. This Support Agreement and the obligations of Stockholders under this Support Agreement shall automatically
terminate and any waivers of rights by Stockholders under this Support Agreement shall automatically be reinstated, in each case, upon
the earliest of: (i) the Effective Time; (ii) the termination of the Merger Agreement in accordance with Section 9.1 thereof; and (iii)
the mutual written agreement of the Parent and the Stockholders. Upon the termination or expiration of this Support Agreement, no party
hereto shall have any further obligations or liabilities under this Support Agreement; provided, however, such termination or expiration
shall not relieve any party hereto from liability for any willful breach of this Support Agreement occurring prior to its termination.

 

16.             
Stockholder Representations: Each Stockholder represents and warrants to the Company, as of the date hereof and as of the
Closing Date, that:

 

		a.	such Stockholder has never been suspended
                                            or expelled from membership in any securities or commodities exchange or association or had
                                            a securities or commodities license or registration denied, suspended or revoked;

 

		b.	such Stockholder has full right and power,
                                            without violating any agreement to which it is bound (including, without limitation, any
                                            non-competition or non-solicitation agreement with any employer or former employer), to enter
                                            into this Support Agreement;

 

		c.	in the case of any entity, it is duly organized
                                            or formed, as applicable, validly existing and in good standing under the Laws of the jurisdiction
                                            in which it is organized or formed, as applicable, and the execution, delivery and performance
                                            of this Support Agreement and the consummation of the transactions contemplated hereby are
                                            within such Stockholder’s corporate, partnership or limited liability company powers,
                                            as applicable, and have been duly authorized by all necessary corporation, partnership or
                                            limited liability company actions, as applicable, on the part of such Stockholder;

 

		d.	this Support Agreement has been duly executed
                                            and delivered by such Stockholder and, assuming due authorization, execution and delivery
                                            by the other parties to this Support Agreement, this Support Agreement constitutes a legally
                                            valid and binding obligation of such Stockholder, enforceable against such Stockholder in
                                            accordance with the terms hereof (except as enforceability may be limited by bankruptcy Laws,
                                            other similar Laws affecting creditors’ rights and general principles of equity affecting
                                            the availability of specific performance and other equitable remedies);

 

    	 	7	 

     

    

 

		e.	the execution and delivery of this Support
                                            Agreement by such Stockholder does not, and the performance by such Stockholder of its obligations
                                            hereunder will not, (i) conflict with or result in a violation of the organizational documents
                                            of such Stockholder, or (ii) require any consent or approval from any third party that has
                                            not been given or other action that has not been taken by any third party, in each case,
                                            to the extent such consent, approval or other action would prevent, enjoin or materially
                                            delay the performance by such Stockholder of his, her or its obligations under this Support
                                            Agreement;

 

		f.	there are no Proceedings pending against
                                            such Stockholder or, to the knowledge of such Stockholder, threatened against such Stockholder,
                                            before (or, in the case of threatened Proceedings, that would be before) any arbitrator or
                                            any Governmental Authority, which in any manner challenges or seeks to prevent, enjoin or
                                            materially delay the performance by such Stockholder of his, her or its obligations under
                                            this Support Agreement;

 

		g.	such Stockholder has had the opportunity
                                            to read the Merger Agreement and this Support Agreement and has had the opportunity to consult
                                            with tax and legal advisors of his, her or its own choosing;

 

		h.	such Stockholder has not entered into, and
                                            shall not enter into, any agreement that would prevent or delay such Stockholder from performing
                                            any of its obligations hereunder;

 

		i.	such
                                            Stockholder has good title to the Stockholder Shares set forth opposite such Stockholder’s
                                            name on Exhibit A, free and clear of any Liens, and such Stockholders has the sole
                                            power to vote or cause to be voted such Stockholder Shares; and

 

		j.	the
                                            Stockholder Shares identified in Section 2 of this Support Agreement are the only
                                            voting securities of the Company owned of record or beneficially owned by such Stockholder
                                            as of the date hereof, and none of such Stockholder Shares are subject to any proxy, voting
                                            trust or other agreement or arrangement with respect to the voting of such Stockholder Shares
                                            that is inconsistent with such Stockholder’s obligations pursuant to this Support Agreement
                                            or the disposition of such Stockholder Shares.

 

17.             
Adjustment for Stock Split. If, and as often as, there are any changes in the Company or the Stockholder Shares by way
of stock split, stock dividend, combination or reclassification, or through merger, consolidation, reorganization, recapitalization or
business combination, or by any other means, equitable adjustment shall be made to the provisions of this Support Agreement as may be
required so that the rights, privileges, duties and obligations hereunder shall continue with respect to the Stockholders, the Company
and the Stockholder Shares as so changed.

 

18.             
Further Actions. Each of the parties hereto agrees to execute and deliver hereafter any further document, agreement or
instrument of assignment, transfer or conveyance as may be necessary or desirable to effectuate the purposes hereof and as may be reasonably
requested in writing by another party hereto. 

 

[remainder of page intentionally
left blank]

 

    	 	8	 

     

    

 

If the above correctly reflects
our understanding and agreement with respect to the foregoing matters, please so confirm by signing in the space below and returning this
letter agreement to us.

 

	 	Sincerely,
	 	 	 	 
	 	LUX VENTURES
    IV, L.P.
	 	 	 	 
	 	By: Lux Venture
    Partners IV, LLC, its General Partner
	 	 	 	 
	 	 	 	 
	 	By:	 	/s/
    Peter Herbert 
	 	Name: Peter Herbert
	 	Title: Managing
    Director
	 	 	 	 
	 	 	 	 
	 	LUX
CO-INVEST OPPORTUNITIES, L.P.
	 	 	 	 
	 	By: Lux Co-Invest
    Partners, LLC, its General Partner
	 	 	 	 
	 	 	 	 
	 	By	 	/s/ Peter Herbert
	 	Name: Peter Herbert
	 	Title: Managing
    Director
	 	 	 	 

 

	 	Address:	 	1600 El Camino Real, Suite 290
	 	 	 	Menlo Park, CA, 94025

 

    Signature Page to
Stockholders Support Agreement

     

    

 

	 	PHARMACEUTICAL
    PRODUCT DEVELOPMENT, LLC
	 	 	 	 
	 	 	 	 
	 	By:	 	/s/
    B. Judd Hartman
	 	Name:
    B. Judd Hartman
	 	Title: Executive
    Vice President and Chief Administrative Officer

 

	 	Address:	 	929 North Front Street
	 	 	 	Wilmington, NC 28401

 

 

    Signature Page to
Stockholders Support Agreement

     

    

 

	 	REDMILE PRIVATE
    INVESTMENTS II, L.P.
	 	 	 	 
	 	By: Redmile Private
    Investments II (GP), LLC, its general partner
	 	 	 	 
	 	By: Redmile Group,
    LLC, its managing member
	 	 	 	 
	 	 	 	 
	 	By:	 	/s/
    Joshua Garcia
	 	Name: Joshua Garcia
	 	Title: Authorized
    Signatory
	 	 	 	 
	 	 	 	 
	 	REDMILE CAPITAL
    OFFSHORE II MASTER FUND, LTD.
	 	 	 	 
	 	By: Redmile Group,
    LLC, its investment manager
	 	 	 	 
	 	By:	 	/s/
    Joshua Garcia
	 	Name: Joshua Garcia
	 	Title: Authorized
    Signatory
	 	 	 	 
	 	 	 	 
	 	REDMILE STRATEGIC
    MASTER FUND, LP
	 	 	 	 
	 	By: Redmile Group,
    LLC, its investment manager
	 	 	 	 
	 	By:	 	/s/
    Joshua Garcia
	 	Name: Joshua Garcia
	 	Title: Authorized
    Signatory
	 	 	 	 
	 	 	 	 
	 	RAF,
                                            L.P.

	 	 
	 	By: RAF GP, LLC,
    its general partner
	 	 
	 	 	 	 
	 	By:	 	/s/
    Joshua Garcia
	 	Name: Joshua Garcia
	 	Title: Authorized
    Signatory

 

	 	Address:	 	c/o Redmile Group,
    LLC
	 	 	 	One Letterman Drive
	 	 	 	Building D, Suite D3-300
	 	 	 	San Francisco, CA 94129
	 	 	 	Email: operations@redmilegrp.com
	 	 	 	Attn: Josh Garcia

 

 

    Signature Page to
Stockholders Support Agreement

     

    

 

	 	DRX CAPITAL
    AG
	 	 	 	 
	 	By:	 	/s/
    Neil Tiwari
	 	Name: Neil Tiwari
	 	Title: General Partner

 

	 	Address:	 	44 Montgomery
	 	 	 	San Francisco, CA

 

 

    Signature Page to
Stockholders Support Agreement

     

    

 

	 	/s/ David Coman
	 	David Coman

 

 

    Signature Page to
Stockholders Support Agreement

     

    

 

	 	/s/ Laura Podlsky
	 	Laura Podlsky

 

 

    Signature Page to
Stockholders Support Agreement

     

    

 

	 	/s/
    Jonathan Reitman
	 	Jonathan Reitman

 

 

    Signature Page to
Stockholders Support Agreement

     

    

 

	 	/s/
    Anita Modi
	 	Anita Modi

  

 

    Signature Page to
Stockholders Support Agreement

     

    

 

	 	LIFESCI VENTURE
    PARTNERS II, LP
	 	 	 	 
	 	 	 	 
	 	By:	 	/s/ Andrew McDonald
	 	Name: Andrew McDonald
	 	Title: Partner

 

 

    Signature Page to
Stockholders Support Agreement

     

    

 

Accepted and Agreed:

 

SCIENCE 37, INC.

 

 

	By:	 	/s/
    David Coman	 
	 	 	 	 	 	 
	 	 	Name:	 	David Cowan	 
	 	 	Title:	 	Chief Executive Officer	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	LIFESCI ACQUISITION
    II CORP.	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	By:	 	/s/
    Andrew McDonald	 
	 	 	 	 	 	 
	 	 	Name:	 	Andrew McDonald	 
	 	 	Title:	 	CEO	 

 

    Signature Page to
Stockholders Support Agreement

     

    

 

EXHIBIT A

 

LIST OF STOCKHOLDERS

 

	
     

    Name of Stockholder
	Number of Shares of Company Common Stock Owned	Number of Shares of Company Preferred Stock Owned
	Pharmaceutical Product Development, LLC	0	9,298,410
	Lux Ventures IV, L.P.	0	6,422,296
	dRx Capital AG	0	5,651,398
	Redmile Private Investments II, L.P.	0	3,995,153
	RAF, L.P.	0	2,109,251
	Lux Co-Investment Opportunities, L.P.	0	1,765,997
	Redmile Capital Offshore II Master Fund, Ltd.	0	1,713,503
	LifeSci Venture Partners II, LP	0	1,016,831
	Redmile Strategic Master Fund LP	0	339,360
	David Coman	304,000	0
	Laura Podolsky	299,307	32,284
	Jonathan Reitman	195,025	32,284
	Anita Modi	50,000	0

 

 

Exhibit A

     

     

    

 

EXHIBIT B

 

COMPANY FINANCING AGREEMENTS

 

1. Amended and Restated Investors’ Rights Agreement, dated as
of August 5, 2020, by and among the Company and each of the investors listed on Schedule A attached thereto.

 

2. Amended and Restated Voting Agreement, dated as of August 5, 2020,
by and among the Company, the holders of the Company’s Preferred Stock listed on the Schedule of Investors attached as Schedule
A thereto, and the holders of the Company’s Common Stock listed on the Schedule of Key Holders attached as Schedule B thereto, and
any subsequent stockholders, or any transferees who became party thereto.

 

3. Amended and Restated First Refusal and Co-Sale Agreement, dated
as of August 5, 2020, by and among the Company, the holders of Company Common Stock listed on Schedule A attached thereto, and the holders
of Company Preferred Stock listed on Schedule B attached thereto.

 

 

 

Exhibit BEX-10.10

   

  Exhibit 10.10

   

  Icosavax, Inc.

   

  August 9, 2021

   

  Via Email

   

  Elizabeth Bekiroglu 

   

  	Re:	Employment Letter Agreement

   

  Dear Elizabeth:

   

  	Icosavax, Inc. (the “Company”) is pleased to offer you (the “Employee”) a position on the terms set forth in this letter (this “Agreement”).  In consideration of the mutual promises herein contained, the parties agree as follows: 

   

  1.Commencement of Employment. Employee’s employment with the Company will commence on September 7, 2021 (the “Effective Date”). 

  2.Position. Employee will serve in the position of General Counsel and Corporate Secretary.  Employee will report to the Company’s Chief Executive Officer, and shall be responsible for the duties customarily associated with this position and such other duties assigned by the Company. Employee will work at the Company’s facility located at Seattle, Washington. Subject to the protections set forth in Sections 8 and 9 below, the Company may change Employee’s position, duties, and work location from time to time in its discretion. Employee will be employed on a full-time basis.  This is an exempt position.  

  3.Base Salary and Employee Benefits. 

  (a)Salary.	Employee’s base salary will be $375,000.00 per year (the “Base Salary”), paid on the Company’s normal payroll schedule.  

  (b)Benefits. During her employment, Employee will be eligible to participate in the standard benefits plans offered to similarly situated employees by the Company from time to time, subject to plan terms and generally applicable Company policies. A full description of these benefits will be available upon request. Employee will be eligible to accrue vacation or paid time off in accordance with the Company’s policies as in effect from time to time. The Company may change compensation and benefits from time to time in its discretion.

  (c)Expenses.  All reasonable business expenses that are documented by Employee and incurred in the ordinary course of business will be reimbursed in accordance with the Company’s standard policies and procedures.

  4.Annual Bonus. Commencing with 2021, Employee will be eligible to earn an annual performance bonus of up to forty percent (40%) of Employee’s Base Salary rate (the “Annual Bonus”) for performance at “targeted” levels.  The Annual Bonus will be based upon an assessment by the Board of Directors of the Company (the “Board”) or its Compensation Committee , of Employee’s performance and the Company’s attainment of written targeted goals as set by the Board in its sole discretion.  Following the close of each calendar year, the Board will determine whether Employee has earned an Annual Bonus, and the amount of any such bonus, based on the achievement of such goals.  No amount of the Annual Bonus 

  Page 1

  |US-DOCS\120726369.2||

  

   

  is guaranteed, and Employee must be an employee on the Annual Bonus payment date to be eligible to receive an Annual Bonus; except as provided in the following sentence or in Section 8 below, no partial or prorated bonuses will be provided.  The Annual Bonus, if earned, will be paid no later than March 15 of the calendar year after the applicable bonus year.  Employee’s Annual Bonus for 2021 will be prorated to reflect the portion of the year following the Effective Date.   

  5.Signing Bonus. Employee shall be entitled to receive a signing bonus in the amount of $50,000, payable in a single lump-sum cash payment within thirty (30) days following the Effective Date (the “Signing Bonus”). In the event that Employee voluntarily resigns her employment with the Company prior to the first anniversary of the Effective Date other than for Good Reason (as defined below), Employee shall be required to repay to the Company a prorated portion of the Signing Bonus based on the number of days elapsed in the twelve months following the Employee’s Effective Date through the date of termination. Any amount required to be repaid shall be repaid to the Company no later than thirty (30) days following Employee’s termination of employment. 

  6.Equity Awards.  

  (a)Subject to approval by the Board or its Compensation Committee, Employee will be granted a stock option to purchase 222,250 shares of the Company’s common stock (the “Stock Option”).  The Stock Option will be granted pursuant to the Company’s equity incentive plan (the “Plan”), and will be subject to the terms and conditions of the Plan and the form of stock option agreement thereunder.  The Stock Option will have an exercise price per share equal to the fair market value per share of the Company’s common stock on the effective date of grant, which pursuant to the Plan will be equal to the closing price per share of the Company’s common stock on the effective grant date  .  Subject to Section 9 below, the Stock Option will vest over a period of four (4) years, with 25% of the original shares underlying the Stock Option vesting on the first anniversary of the Effective Date, and 1/48th of the original number of shares subject to the Stock Option vesting on each monthly anniversary of the Effective Date thereafter. 

  (b)Subject to approval by the Board or a committee thereof, Employee will be granted 27,750 restricted stock units (the “RSUs”).  The RSUs will be granted pursuant to the Plan, and will be subject to the terms and conditions of the Plan and the form of RSU agreement thereunder.  Subject to Section 8 below, the RSUs will vest over a period of four (4) years in four equal annual installments on each of the first four (4) anniversaries of the Effective Date. 

  7.At-Will Employment Relationship. Employee may terminate her employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate Employee’s employment at any time, with or without cause or advance notice.  Employee’s employment at-will status can only be modified in a written agreement signed by Employee and by an officer of the Company. 

  8.Severance Benefits.  If, at any time, the Company terminates Employee’s employment without Cause (as defined below) or Employee resigns for Good Reason (either such termination referred to as a “Qualifying Termination”), provided such termination or resignation also constitutes a Separation from Service (as defined below), then subject to Sections 11, 12 and 13 below, Employee’s continued compliance with the terms of this Agreement (including without limitation Sections 15, 16 and 17 below) and Employee’s resignation from any and all positions Employee may hold with the Company, to be effective no later than Employee’s Separation from Service date (or such other date requested or permitted by the Board or the Company’s Chief Executive Officer), the Company will provide Employee with the following severance benefits (the “Severance Benefits”):

  Page 2

  |US-DOCS\120726369.2||

  

   

  (a)Cash Severance.  Upon a Qualifying Termination, the Company will pay Employee, as cash severance (i) Employee’s Base Salary in effect as of Employee’s Separation from Service date for the Severance Period (the “Base Severance”), plus (ii) (A) in the event such Qualifying Termination does not occur during the Change in Control Period, an amount equal to Employee’s “target” Annual Bonus for the year in which Employee’s Qualifying Termination occurs, prorated to reflect the portion of the year that has elapsed prior to the date of Employee’s Separation from Service date, or (B) in the event such Qualifying Termination does occur during the Change in Control Period, an amount equal to one hundred percent (100%) multiplied by Employee’s “target” Annual Bonus for the year in which Employee’s Qualifying Termination occurs (the “Bonus Severance,” and with the “Base Severance,” the “Severance”).  

   

  Except in the case of a Qualifying Termination that occurs within eighteen (18) months following  a Change in Control, the Base Severance will be paid in installments in the form of continuation of Employee’s Base Salary payments over the Severance Period, paid on the Company’s ordinary payroll dates, commencing on the sixtieth (60th) day following Employee’s Separation from Service date.  The first such installment shall be for any accrued Base Salary for the sixty (60)-day period preceding such initial payment date. All salary continuation payments thereafter, if any, shall be made on the Company’s regular payroll dates. 

   

  In the case of a Qualifying Termination that occurs within eighteen (18) months following a Change in Control, the Base Severance will be paid in a lump sum on the sixtieth (60th) day following Employee’s Separation from Service date. 

   

  Any Bonus Severance will be paid in a lump sum on the sixtieth (60th) day following Employee’s Separation from Service date. 

   

  (b)COBRA Severance.  As additional severance, in the event of Employee’s Qualifying Termination, the Company will continue to pay the cost of Employee’s health care coverage in effect at the time of Employee’s Separation from Service for the Severance Period (the “COBRA Coverage Period”), either under the Company’s regular health plan (if permitted) or by paying Employee’s COBRA premiums (the “COBRA Severance”).  The Company’s obligation to pay the COBRA Severance on Employee’s behalf will cease if Employee obtains health care coverage from another source (e.g., a new employer or spouse’s benefit plan), unless otherwise prohibited by applicable law.  Employee must notify the Company within two (2) weeks if Employee obtains coverage from a new source.  This payment of COBRA Severance by the Company would not expand or extend the maximum period of COBRA coverage to which Employee would otherwise be entitled under applicable law.  Notwithstanding the above, if the Company determines in its sole discretion that it cannot provide the foregoing COBRA Severance without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), or if the Company otherwise elects, in its sole discretion, the Company shall in lieu thereof provide to Employee a taxable monthly payment in an amount equal to the monthly COBRA premium that Employee would be required to pay to continue Employee’s group health coverage in effect on the date of Employee’s termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether Employee elects COBRA continuation coverage and shall end on the earlier of (x) the date upon which Employee obtains other coverage or (y) the last day of applicable COBRA Coverage Period. 

   

  9.Accelerated Vesting.  Subject to Sections 11, 12 and 13 below, Employee’s continued compliance with the terms of this Agreement (including without limitation Sections 15, 16 and 17 below), Employee’s resignation from any and all positions Employee may hold with the Company, to be effective no later than Employee’s Separation from Service date (or such other date requested or permitted by the Board or the Company’s Chief Executive Officer), the Company will provide Employee with the following accelerated vesting (the “Accelerated Vesting”):

  Page 3

  |US-DOCS\120726369.2||

  

   

  	(a)	In the event of Employee’s Qualifying Termination not occurring during the Change in Control Period, then such number of shares underlying Employee’s Stock Awards shall be deemed vested effective immediately prior to such termination as would have vested by the terms of such awards during the nine (9) months following Employee’s date of termination had Employee remained employed by the Company during such period; and 

  	(b)	In the event of Employee’s Qualifying Termination during the Change in Control Period, all of Employee’s Stock Awards shall vest effective upon the later of (i) the date of termination or (ii) the date of the Change in Control. 

  Except to the extent an award agreement governing a Stock Award granted to Employee specifically provides for the treatment of such Stock Award in the event of any of the acceleration events described in this Section 9 and provides that its terms shall supersede the provisions of this Section 9, in which case the terms of such award agreement shall govern, the foregoing Accelerated Vesting provisions are deemed to be a part of each Stock Award and to amend and supersede any less favorable provision in any agreement or plan regarding such Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting than the Accelerated Vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable provisions shall continue to apply and shall not be limited by the Accelerated Vesting).

  10.Resignation Without Good Reason; Termination for Cause; Death or Disability.  If, at any time, Employee resigns her employment with the Company without Good Reason, or the Company terminates Employee’s employment for Cause, or Employee’s employment with the Company terminates for any reason not entitling Employee to the Severance Benefits or Accelerated Vesting pursuant to Sections 8 and 9 above, including as a result of Employee’s death or disability, then Employee will receive her Base Salary accrued through her last day of employment.  Under these circumstances, Employee will not be entitled to any other form of compensation from the Company, including any Severance Benefits or Accelerated Vesting, other than Employee’s rights to the vested portion of Employee’s Stock Awards and any other rights to which Employee is entitled under the Company’s benefit programs or applicable law.  In addition, Employee shall resign from any and all positions Employee holds with the Company, with such resignations to be effective no later than the date of Employee’s employment termination (or such other date requested or permitted by the Board or the Company’s Chief Executive Officer). 

  11.Conditions to Receipt of Severance Benefits and Accelerated Vesting.  Prior to and as a condition to Employee’s receipt of the Severance Benefits or Accelerated Vesting described above, Employee shall timely execute and deliver to the Company a release of claims in favor of and in a form acceptable to the Company (the “Release”) and allow the Release to become effective according to its terms (by not invoking any legal right to revoke it) within sixty (60) days following Employee’s Separation from Service date.

  12.Compliance with Section 409A.  It is intended that the Severance Benefits and Accelerated Vesting set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code (Section 409A, together with any state law of similar effect, “Section 409A”) provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9).  For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulations 1.409A-2(b)(2)(iii)), Employee’s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.  Notwithstanding any provision to the contrary in this Agreement, if the Company (or, if applicable, the successor entity thereto) determines that the Severance Benefits or Accelerated Vesting constitute “deferred compensation” under Section 409A and Employee is, on the date of 

  Page 4

  |US-DOCS\120726369.2||

  

   

  Employee’s Separation from Service, a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of adverse personal tax consequences under Section 409A, the timing of the Severance Benefits and Accelerated Vesting shall be delayed until the earliest of: (a) the date that is six (6) months and one (1) day after Employee’s Separation from Service date, (b) the date of Employee’s death, or (c) such earlier date as permitted under Section 409A without the imposition of adverse taxation.  Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments or benefits deferred pursuant to this Section 12 shall be paid in a lump sum or provided in full by the Company (or the successor entity thereto, as applicable), and any remaining payments due shall be paid as otherwise provided herein. No interest shall be due on any amounts so deferred.  The Severance Benefits and Accelerated Vesting are intended to qualify for an exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. Any reimbursement of expenses or in-kind benefits payable under this Agreement shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of Employee’s taxable year following the taxable year in which Employee incurred the expenses.  The amount of expenses reimbursed or in-kind benefits payable in one year shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Employee, and Employee’s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit. For purposes of this Agreement, all references to Employee’s “termination of employment” shall mean Employee’s Separation from Service. 

  13.Section 280G Treatment.  

  	(a)	In the event that any payment or benefit received or to be received by Employee pursuant to the terms of any plan, arrangement or agreement (including any payment or benefit received in connection with a change of control or the termination of Employee’s employment) (all such payments and benefits being hereinafter referred to as the “Total Payments”) would be subject (in whole or part) to the excise tax (the “Excise Tax”) imposed under Section 4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but only if (i) the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii) the net amount of such Total Payments without such reduction (after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which Employee would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).  The Total Payments shall be reduced in the following order: (A) reduction of any cash severance payments otherwise payable to Employee that are exempt from Section 409A of the Code, (B) reduction of any other cash payments or benefits otherwise payable to Employee that are exempt from Section 409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award with respect to the Company’s common stock that is exempt from Section 409A of the Code, (C) reduction of any other payments or benefits otherwise payable to Employee on a pro-rata basis or such other manner that complies with Section 409A of the Code, but excluding any payment attributable to the acceleration of vesting and payment with respect to any equity award with respect to the Company’s common stock that is exempt from Section 409A of the Code, and (D) reduction of any payments attributable to the acceleration of vesting or payment with respect to any equity award with respect to the Company’s common stock that is exempt from Section 409A of the Code; provided, in case of clauses (B), (C) and (D), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.  The foregoing reductions shall be made in a manner that results in the maximum economic 

  Page 5

  |US-DOCS\120726369.2||

  

   

  benefit to Employee on an after-tax basis and, to the extent economically equivalent payments or benefits are subject to reduction, in a pro rata manner. 

  	(b)	All determinations regarding the application of this “Section 280G Treatment” section shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in control (the “280G Firm”).  For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (i) no portion of the Total Payments shall be taken into account which, in the written opinion of the 280G Firm, (A) does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (B) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the "base amount" (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation, (ii) no portion of the Total Payments the receipt or enjoyment of which Employee shall have waived at such time and in such manner as not to constitute a “payment” within the meaning of Section 280G(b) of the Code shall be taken into account, and (iii) the value of any non-cash benefit or any deferred payment or benefit included in the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.  All determinations related to the calculations to be performed pursuant to this “Section 280G Treatment” section shall be done by the 280G Firm.

  	(c)	The 280G Firm will be directed to submit its determination and detailed supporting calculations to both Employee and the Company within fifteen (15) days after notification from either the Company or Employee that Employee may receive payments which may be “parachute payments.”  Employee and the Company will each provide the 280G Firm access to and copies of any books, records, and documents in their possession as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement.  The fees and expenses of the 280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be borne solely by the Company.

  14.Withholding Taxes.  All amounts payable to Employee will be subject to reduction to reflect applicable withholding and payroll taxes.

  15.Compliance with Confidential Information and Inventions Agreement and Company Policies.  In the performance of services for the Company, Employee will be expected to abide by Company rules and policies. Employee acknowledges that she will be required, concurrently with the execution of this Agreement and as a condition of her employment, to execute the Company’s Confidential Information and Inventions Assignment Agreement (the “Confidential Information and Inventions Assignment Agreement”), attached hereto as Exhibit A, which prohibits unauthorized use or disclosure of the Company’s proprietary information, among other obligations. Employee agrees to perform each and every obligation of Employee therein contained. Notwithstanding the foregoing or as provided in the Confidential Information and Inventions Assignment Agreement, pursuant to 18 U.S.C. Section 1833(b), Employee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (a) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

  16.Protection of Third Party Information.  In Employee’s work for the Company, Employee will be expected not to use or disclose any confidential information, including trade secrets, of any former 

  Page 6

  |US-DOCS\120726369.2||

  

   

  employer or other person to whom Employee has an obligation of confidentiality. Rather, Employee will be expected to use only that information which is generally known and used by persons with training and experience comparable to her own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. Employee agrees that Employee will not bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom Employee has an obligation of confidentiality. Employee hereby represents that she has disclosed to the Company any contract she has signed that may restrict her activities on behalf of the Company.

  17.Return of Company Property.  Upon the termination of Employee’s employment with the Company for any reason, Employee will return to the Company all Company documents (and all copies thereof) and other Company property within their possession, custody or control, including but not limited to Company files, notes, financial and operational information, customer lists and contact information, investor and finance source lists and contract information, product information, research and development information, drawings, records, plans, forecasts, reports, payroll information, spreadsheets, studies, analyses, compilations of data, proposals, agreements, sales and marketing information, personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including but not limited to computers, facsimile machines, mobile telephones, tablets, handheld devices and servers), credit cards, entry cards, identification badges and keys, and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part and in any medium).  Employee shall deliver to the Company, upon request, a signed statement certifying compliance with this Section 17.

  18.Exclusive Services. Employee shall at all times faithfully, industriously and to the best of Employee’s ability, experience and talent perform to the satisfaction of the Board all of the duties that may be assigned to Employee hereunder and shall devote substantially all of her productive time and efforts to the performance of such duties.  Subject to the terms of the Confidential Information and Inventions Assignment Agreement, this shall not preclude Employee from devoting time to personal and family investments or serving on community and civic boards, or participating in industry associations, provided such activities do not interfere with the duties to the Company, as determined in good faith by the Board.  Employee agrees that she will not join any boards, other than community and civic boards (which do not interfere with Employee’s duties to the Company), without the prior approval of the Company.  The Company may require termination of Employee’s participation in other business or public activities if the Company, in its sole discretion, determines that such activities compromise or threaten to compromise the Company’s business interests or conflict with Employee’s duties to the Company.  During Employee’s employment by the Company, except on behalf of the Company, Employee will not directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of any other person, corporation, firm, partnership or other entity whatsoever known by Employee to compete with the Company (or is planning or preparing to compete with the Company), anywhere in the world; provided, however, that Employee may purchase or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. If the Board determines Employee is in breach of this Section 18, and provided such breach is not cured within thirty (30) days of written notification of such breach from the Board, then the Company may terminate Employee’s employment for Cause. 

  19.Dispute Resolution.  To ensure the rapid and economical resolution of disputes that may arise in connection with Employee’s service or employment with the Company, Employee and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, Employee’s service or employment with the Company, or the termination 

  Page 7

  |US-DOCS\120726369.2||

  

   

  of such service or employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in the city of the Company’s then principal place of business in the United States conducted by JAMS or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at http://www.jamsadr.com/rules-employment-arbitration/). Employee acknowledges that by agreeing to this arbitration procedure, she waives the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. Employee will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that Employee or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that Employee would be required to pay if the dispute were decided in a court of law. The parties agree this arbitration agreement does not extend to claims for workers’ compensation or unemployment benefits, or any other claims, that Employee cannot, as a matter of applicable law, be required to arbitrate, nor does it preclude Employee from initiating a complaint before the Equal Employment Opportunity Commission or any other governmental agency, but if any such complaint is not resolved before the agency any action for money damages shall be submitted to arbitration pursuant to this paragraph.  Nothing in this Agreement is intended to prevent any party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.

  20.Miscellaneous.  This Agreement, with the Confidential Information and Inventions Assignment Agreement and the Indemnification Agreement by and between the Employee and the Company executed in connection with Employee’s commencement of employment, form the complete and exclusive statement governing Employee’s employment with the Company.  They supersede any other agreements or promises made to Employee by anyone, whether oral or written.  Changes in the terms of Employee’s employment, other than those changes expressly reserved to the Company’s or the Board’s discretion in this Agreement, require a written modification approved by the Company and signed by a duly authorized officer of the Company.  This Agreement will bind the heirs, personal representatives, successors and assigns of Employee and the Company, and inure to the benefit of Employee and the Company, their heirs, successors and assigns.  If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law.  This Agreement shall be construed and enforced in accordance with the laws of the State of Washington without regard to conflicts of law principles.  Any ambiguity in this Agreement shall not be construed against any party as the drafter.  Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder.  This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.

  21.Definitions.  For purposes of this Agreement, the following terms shall have the following meanings:

  (a)“Cause” shall mean the occurrence of any of the following events, in each instance that has a material adverse impact on the Company or any successor or affiliate thereof as determined by the Chief Executive Officer in its reasonable discretion: (i) Employee’s conviction of, or plea of “guilty” or “no contest” to, any non-vehicular felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) Employee’s commission of, or participation in, a fraud or act of dishonesty or other illegal act against the Company that has a demonstrable adverse impact 

  Page 8

  |US-DOCS\120726369.2||

  

   

  on the Company or any successor or affiliate thereof; (iii) Employee’s intentional, material violation of any contract or agreement between Employee and the Company or any material Company policy or of any statutory duty owed to the Company; (iv) Employee’s intentional unauthorized use or disclosure of the Company’s confidential information or trade secrets; (v) Employee’s gross misconduct; or (vi) Employee’s ongoing and repeated failure or refusal to perform or neglect of Employee’s duties as required by this Agreement or Employee’s ongoing and repeated failure or refusal to comply with the lawful instructions given to Employee by the Chief Executive Officer, which failure, refusal or neglect continues for thirty (30) days following Employee’s receipt of written notice from the Chief Executive Officer stating with specificity the nature of such failure, refusal or neglect; provided that it is understood that this clause (vi) shall not permit the Company to terminate Employee’s employment for Cause solely because of (A) Employee’s failure to meet specified performance objectives or achieve a specific result or outcome, or (B) Company’s dissatisfaction with the quality of services provided by Employee in the good faith performance of Employee’s duties to the Company; provided, that, with respect to (iii), (iv), (v) and (vi) above, “Cause” will be triggered after Employee has received written notification of such failure from the Chief Executive Officer, which, if curable, remains uncured after thirty (30) days written notice from the Chief Executive Officer. Employee shall be provided an opportunity to be heard prior to the final decision to terminate Employee’s employment hereunder for such “Cause,” and any determination of Cause by the Chief Executive Officer or the Company will be made in good faith. 

  (b)“Change in Control” shall have the meaning given to such term in the Company’s 2021 Incentive Award Plan.  Notwithstanding the foregoing, if a Change in Control would give rise to a payment or settlement event with respect to any payment or benefit that constitutes “nonqualified deferred compensation,” the transaction or event constituting the Change in Control must also constitute a “change in control event” (as defined in Treasury Regulation §1.409A-3(i)(5)) in order to give rise to the payment or settlement event for such payment or benefit, to the extent required by Section 409A.

   

  (c)“Change in Control Period” shall mean the period commencing sixty (60) days prior to and ending eighteen (18) months following a Change in Control. 

  (d)“Good Reason” shall mean any of the following actions taken without Cause by the Company or a successor corporation or entity without Employee’s consent: (i) material reduction of Employee’s base compensation (and Employee and the Company agree that any diminution of ten percent (10%) or more shall be considered material for this purpose, regardless of whether such diminution occurs due to a single reduction or a series of reductions in Employee’s base compensation), other than to the extent the base compensation of all of the executive officers of the Company are concurrently reduced by the same or greater percentage; (ii) material reduction in Employee’s authority, duties or responsibilities, provided, however, that a change in Employee’s job position or title shall not be deemed a “material reduction” unless Employee’s new authority, duties or responsibilities are materially reduced from the prior authority, duties or responsibilities; (iii) relocation of the principal place at which Employee is required to provide services to the Company or Employee’s principal place of employment that results in an increase in Employee’s one-way driving distance by more than fifty (50) miles from Employee’s then current principal place of business or residence, as applicable; and (iv) any other action or inaction that constitutes a material breach by the Company or any successor or affiliate of its obligations to Employee under this Agreement  In order to resign for Good Reason, Employee must provide written notice of the event giving rise to Good Reason to the Company within ninety (90) days after the condition arises, allow the Company thirty (30) days to cure such condition, and if the Company fails to cure the condition within such period, then Employee’s resignation from all positions Employee then holds with the Company must be effective not later than ninety (90) days after the end of the Company’s cure period. 

  (e)“Separation from Service” shall mean a “separation from service” as such term is defined in Treasury Regulation Section 1.409A-1(h).

  Page 9

  |US-DOCS\120726369.2||

  

   

  (f)“Severance Period” shall mean (i) if Employee’s Qualifying Termination does not occur during the Change in Control Period, nine (9) months, and (ii) if Employee’s Qualifying Termination occurs during the Change in Control Period, twelve (12) months. 

  (g)“Stock Awards” shall mean means all stock options, restricted stock, restricted stock units and such other awards granted pursuant to the Company’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof.

  22.	Conditions to Employment.  As a condition to Employee’s employment with the Company, Employee is required to (a) sign and return a satisfactory I-9 Immigration form providing sufficient documentation establishing Employee’s employment eligibility in the United States, and (b) provide satisfactory proof of Employee’s identity as required by United States law.  In the event these conditions are not satisfied on or prior to the Effective Date, or in the event Employee fails to sign and return the Confidential Information and Inventions Assignment Agreement on or prior to the Effective Date, this offer of employment shall be revoked and this Agreement shall terminate and be of no further force or effect.

   (Signature Page Follows) 

   

  Page 10

  |US-DOCS\120726369.2||

  

   

  Sincerely,

   

  Icosavax, Inc.

   

  By:   /s/ Adam K. Simpson		

  Adam K. Simpson, Chief Executive Officer

  Acknowledged and Agreed:

  /s/ Elizabeth Bekiroglu				

  Elizabeth Bekiroglu 

   

   

   

   

  Page 11

  |US-DOCS\120726369.2||

  

   

  Exhibit A

   

  Confidential Information and Inventions Assignment Agreement 

   

   

   

   

   

  Page 12

  |US-DOCS\120726369.2||

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]